Cheaper copy of herceptin tested for stomach cancer – small study shows promise
NCT ID NCT04181333
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study by Pfizer tested a biosimilar (a near-copy) of trastuzumab in 8 people with advanced or recurrent HER2-positive gastric cancer that could not be removed by surgery. The goal was to check safety and how well the drug worked in real-world use. Participants received the biosimilar alongside other anti-cancer drugs, and doctors tracked side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab biosimilar (a copy of Herceptin)
What this could lead to
If this biosimilar works as well as the original drug, it could offer a more affordable treatment option for HER2-positive gastric cancer.
What could go wrong
This was a very small study (8 people) with no comparison group. Results may not apply to all patients, and biosimilars can have subtle differences in safety or effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, Japan